策点调研公司 | Ceidea | China Market Research Company | China Market Entry | China Market Analysis

Life Sciences

Home >> Views >> Life Sciences

Drug Firm Expects Growth to Double

Source：CCMR Data：2012-3-1

BRISTOL-MYERS Squibb yesterday said it expects its China sales to grow by 27 percent this year, double the growth in 2011, based on strong demand for its key hepatitis and diabetes products.

Last year, its sales in China grew 13 percent annually, beating its global growth of 9 percent.

"We plan to introduce at least two new prescription drugs to the Chinese market this year and focus on getting more new innovative products registered in China," Jean-Christophe Pointeau, president of BMS China, said yesterday.

·Chinese Healthcare Spending

·Monthly Output of Chinese Patent Medicine, Jan.2011-Oct.2012

·Fairwood (HKG:0052) repurchases 41K shares

·Interchina (HKG:0202) places shares for $359M

·Venturepharm (HKG:8225) to halt trading for results release

·Wuyi Pharma (HKG:1889) 2011 net profit RMB57M, down 46%; div HK$0.008

·Lijun (HKG:2005) sinks to red, 2011 NL $41M; div 2 ct

·Healthy Living

·BMS Banks on Innovative Drugs to Double China Sales

·Genetic Technologies executes agreement with Eurofins STA

·Takeda announces establishment of development center in China

·Roche supports animal conservation research

·Fudan-Zhangjiang (HKG:8231) Sees 2011 Net Profit Up Sharply

·IDT acquires 1st BASE oligonucleotide business

·BioDiem licenses LAIV technology to Changchun BCHT

Copyright © 2012-2020 策点调研公司 | Ceidea | China Ceidea Market Research Co., LTD Inc. All rights reserved.
Add：No. 2, Jiapin Second Street, Shatou Street, Panyu District, Guangzhou City, Building 1, Room 1805 Tel：+86 13503051005 sandy
粵ICP备13082131号-8